title: Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer.
abstract: BACKGROUND
  Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer.
  
  
  METHODS
  One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker.
  
  
  RESULTS
  FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16.
  
  
  CONCLUSIONS
  FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer. © 2014 Wiley Periodicals, Inc. Head Neck 36: 1253-1257, 2014.
authors.affiliation: Department of Otorhinolaryngology / Head and Neck Surgery, University of Bonn, Germany; Department of Prostate Cancer Research, University of Bonn, Bonn, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Schröck
authors.forename: Friederike
authors.initials: F
authors.lastname: Göke
authors.forename: Patrick
authors.initials: P
authors.lastname: Wagner
authors.forename: Maike
authors.initials: M
authors.lastname: Bode
authors.forename: Alina
authors.initials: A
authors.lastname: Franzen
authors.forename: Sebastian
authors.initials: S
authors.lastname: Huss
authors.forename: Abbas
authors.initials: A
authors.lastname: Agaimy
authors.forename: Stephan
authors.initials: S
authors.lastname: Ihrler
authors.forename: Robert
authors.initials: R
authors.lastname: Kirsten
authors.forename: Glen
authors.initials: G
authors.lastname: Kristiansen
authors.forename: Friedrich
authors.initials: F
authors.lastname: Bootz
authors.forename: Claudia
authors.initials: C
authors.lastname: Lengerke
authors.forename: Sven
authors.initials: S
authors.lastname: Perner
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D015331:Cohort Studies; D018304:Esthesioneuroblastoma, Olfactory / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D005260:Female; D005784:Gene Amplification / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D018308:Papilloma, Inverted / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D010255:Paranasal Sinus Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000235:genetics*
chemical_list: D051496:Receptor, Fibroblast Growth Factor, Type 1
keywords: amplification; cancer; fibroblast growth factor receptor 1 (FGFR1); sinonasal; therapy